Amgen Company Analysis

Amgen Company Analysis

  • June 2018 •
  • 36 pages •
  • Report ID: 5780164 •
  • Format: PDF
PharmaVitae explores Amgen’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Snapshot
Overview – PharmaVitae forecasts Amgen’s sales to grow modestly out to 2027 owing to significant biosimilar exposure and a depleted launch portfolio.
Key themes – [1] Amgen has significant biosimilar exposure [2] Amgen’s launch portfolio appears depleted compared to competitors [3] Kyprolis is proving a dominant force in multiple myeloma
Q1 2018 – Recent sales growth masks ongoing risk of the pipeline failing to offset legacy portfolio decline.

Analysis structure
Explore and visualize revenue dynamics in Amgen’s portfolio out to 2027 using 10-year in-house sales forecasts segmented by the following sections.

Quarterly review

What were the major highlights from Amgen’s latest earnings call and quarterly performance?

Strategy analysis

How is Amgen strategically poised out to 2027?
What are Amgen’s key strengths, weaknesses, opportunities, and threats?
What are Amgen’s key catalysts during the current year?

Portfolio analysis

Why will specific therapy areas experience the largest growth and decline?
What are the detailed competitive dynamics at play in Amgen’s important therapeutic markets?
How is Amgen adapting strategically to internal and external headwinds in preceding quarters?

Facts and figures
What is Amgen’s forecasted sales performance out to 2027?
What is the revenue trajectory of Amgen’s current top 10 products out to 2027?
Which therapy areas will experience the largest growth and decline?
What are the portfolio weightings of Amgen based on the lifecycle of its products?